Gemtuzumab is a monoclonal antibody to [[CD33]] linked to a cytotoxic agent from the class of [[calicheamicin]]s.  CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, the intensity diminishing with maturation of [[stem cells]].

 


 
Common side effects of administration included [[shiver]]ing, [[fever]], [[nausea]] and vomiting. Serious side effects included severe [[myelosuppression]] (suppressed activity of [[bone marrow]], which is involved in formation of various [[blood cell]]s [found in 98% of patients]), disorder of the [[respiratory system]], [[tumor lysis syndrome]], [[Immune complex hypersensitivity|Type III hypersensitivity]], venous occlusion, and death.

 

